Dublin, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The "Diagnostic Collaboration and Licensing Deals 2020-2025" has been added to ResearchAndMarkets.com's offering.
This report contains a comprehensive listing of 1449 diagnostic deals announced since 2020, including financial terms where available, and links to online deal records as disclosed by the deal parties.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the diagnostic deals entered into by the world's leading biopharma companies.
Fully revised and updated, the report provides details of diagnostic deals from 2020 to 2025. The report provides a detailed understanding and analysis of how and why companies enter diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research and licensing deals.
The initial chapters of this report provide an orientation of diagnostic dealmaking. Chapter 1 introduces the report, while Chapter 2 offers an overview of the trends in diagnostic dealmaking since 2020. Chapter 3 reviews the leading diagnostic deals since 2020, sorted by headline value. Chapter 4 lists the top 25 most active companies in diagnostic dealmaking with summaries and a comprehensive listing of deals, including publicly available contracts. Chapter 5 offers a detailed review of diagnostic deals signed and announced since Jan 2020 with available contract documents. Chapter 6 provides insights into diagnostic partnering deals organized by specific diagnostic technology types.
The report also includes numerous tables and figures that illustrate the trends and activities in diagnostic deal making since 2020. In addition, a comprehensive deal directory is provided, organized by company A-Z, deal type, and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2020
- Browse diagnostic collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, deal type, and therapy area
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in diagnostic dealmaking
2.1. Introduction
2.2. Diagnostic deals over the years
2.3. Most active diagnostic dealmakers
2.4. Diagnostic deals by deal type
2.5. Diagnostic deals by therapy area
2.6. Diagnostic deals by industry sector
2.7. Deal terms for diagnostic deals
2.7.1 Diagnostic deals headline values
2.7.2 Diagnostic deal upfront payments
2.7.3 Diagnostic deal milestone payments
2.7.4 Diagnostic royalty rates
Chapter 3 - Leading diagnostic deals
3.1. Introduction
3.2. Top diagnostic deals by value
Chapter 4 - Most active diagnostic dealmakers
4.1. Introduction
4.2. Most active diagnostic dealmakers
4.3. Most active diagnostic deals company profiles
Chapter 5 - Diagnostic contracts dealmaking directory
5.1. Introduction
5.2. Diagnostic contracts dealmaking directory
Chapter 6 - Diagnostic dealmaking by technology type
Deal directory
Deal directory - Diagnostic deals by company A-Z
Deal directory - Diagnostic deals by deal type
Deal directory - Diagnostic deals by therapy area
Deal type definitions
Companies Featured
- 3M
- A2 Biotherapeutics
- Abbott Laboratories
- AEYE Health
- Airinov
- AI Medical Service
- Alere
- AliveCor
- Allergan
- Alta Genetics
- Ambra Health
- American Heart Association
- Amgen
- Angiomed
- Anthem
- Appian
- Array BioPharma
- Asahi Kasei
- AstraZeneca
- Avantor
- Bayer
- BD
- Biogen
- Boston Scientific
- Celgene
- Cerner
- Chembio Diagnostics
- Clariant
- Colgate-Palmolive
- CSL Limited
- Danaher Corporation
- Davita
- Drager
- Eli Lilly and Company
- Exact Sciences
- Fresenius Medical Care
- GE Healthcare
- Hologic
- Honeywell
- Illumina
- Intuitive Surgical
- IQVIA
- Johnson & Johnson
- L'oreal
- Medtronic
- Merck & Co.
- Molnlycke
- Nestle
- Neurocrine Biosciences
- Novo Nordisk
For more information about this report visit https://www.researchandmarkets.com/r/wqoe3a
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
